Science Corporation’s vision-restoring chip wins EU approval
Science Corporation has received EU approval for its PRIMA device, a brain-computer interface designed to restore vision in patients with age-related macular degeneration. The company, founded by former Neuralink executive Max Hodak, aims to build a sustainable business model through medical technology.
Why it matters
This represents a significant milestone in BCI technology, moving from experimental research to regulatory-approved medical treatment for blindness.
Science Corporation, a start-up developing novel brain-computer interfaces (BCI), won approval from Europe’s medical device regulator to begin selling a device that restores vision lost from age-related macular degeneration.
The company said the device, called PRIMA, also received a designation from the US Food and Drug Administration that is the first step toward an expedited regulatory review, which could see the device used to treat two rare kinds of blindness.
Millions of people around the world suffer from age-related macular degeneration, which destroys the light-sensitive cells at the back of the eyes, making it difficult to read and recognize faces.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in